

Augusto Villanueva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8897328/publications.pdf>

Version: 2024-02-01

144
papers

28,029
citations

13827

67
h-index

9073

144
g-index

155
all docs

155
docs citations

155
times ranked

24638
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1450-1462.	13.9	2,966
2	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 6.	18.1	2,757
3	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	9.4	1,372
4	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3129-3140.	1.9	1,237
5	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	13.9	1,148
6	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 149, 1226-1239.e4.	0.6	980
7	Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2009, 69, 7385-7392.	0.4	978
8	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. <i>Gastroenterology</i> , 2017, 152, 745-761.	0.6	838
9	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <i>Gastroenterology</i> , 2017, 153, 812-826.	0.6	650
10	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1972-1983.e11.	0.6	644
11	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.4	589
12	Tumour evolution in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 139-152.	8.2	501
13	β -Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1124-1141.	7.7	498
14	Genomics and Signaling Pathways in Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2007, 27, 055-076.	1.8	491
15	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 408-424.	12.5	456
16	Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. <i>Gastroenterology</i> , 2013, 144, 829-840.	0.6	438
17	Targeted Therapies for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1410-1426.	0.6	408
18	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1501-1512.e2.	0.6	389

#	ARTICLE	IF	CITATIONS
19	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. <i>Gastroenterology</i> , 2006, 131, 1758-1767.	0.6	379
20	DNA methylation-based prognosis and epdrivers in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1945-1956.	3.6	367
21	Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1535-1547.	1.9	341
22	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. <i>Gastroenterology</i> , 2013, 145, 176-187.	0.6	302
23	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. <i>Journal of Clinical Investigation</i> , 2009, 119, 465-477.	3.9	298
24	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 34-42.	8.2	277
25	Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. <i>Seminars in Liver Disease</i> , 2010, 30, 035-051.	1.8	267
26	Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice. <i>Gastroenterology</i> , 2012, 143, 1660-1669.e7.	0.6	262
27	UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 196-209.	7.7	261
28	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	3.2	251
29	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	3.6	235
30	Intratumoral heterogeneity and clonal evolution in liver cancer. <i>Nature Communications</i> , 2020, 11, 291.	5.8	230
31	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. <i>Annual Review of Medicine</i> , 2010, 61, 317-328.	5.0	229
32	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. <i>Journal of Hepatology</i> , 2016, 65, 1031-1042.	1.8	219
33	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. <i>Journal of Hepatology</i> , 2010, 52, 550-559.	1.8	211
34	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	1.8	206
35	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. <i>Gastroenterology</i> , 2011, 140, 1618-1628.e16.	0.6	205
36	Experimental models of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008, 48, 858-879.	1.8	203

#	ARTICLE	IF	CITATIONS
37	Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1024-1030.	0.6	195
38	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , 2019, 68, 1065-1075.	6.1	195
39	A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. <i>Nature Biotechnology</i> , 2009, 27, 264-274.	9.4	194
40	Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. <i>Journal of Hepatology</i> , 2012, 56, 1343-1350.	1.8	181
41	Cancer gene discovery in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 52, 921-929.	1.8	173
42	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	7.7	172
43	Emerging Signaling Pathways in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2012, 1, 83-93.	4.2	169
44	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 73, 315-327.	1.8	164
45	Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. <i>Gut</i> , 2017, 66, 530-540.	6.1	161
46	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. <i>Journal of Hepatology</i> , 2019, 70, 1262-1277.	1.8	150
47	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1325-1331.	1.8	133
48	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	5.7	126
49	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). <i>Gastroenterology</i> , 2021, 161, 879-898.	0.6	123
50	Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 1222-1231.	1.8	121
51	Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. <i>Journal of Hepatology</i> , 2017, 66, 952-961.	1.8	120
52	Pathogenesis of hepatocellular carcinoma and molecular therapies. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 186-194.	1.0	118
53	New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers. <i>Clinical Cancer Research</i> , 2010, 16, 4688-4694.	3.2	114
54	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 806-818.e10.	0.6	109

#	ARTICLE	IF	CITATIONS
55	Mutational landscape of HCC—the end of the beginning. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 73-74.	12.5	108
56	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. <i>Gut</i> , 2016, 65, 1754-1764.	6.1	108
57	Biomarkers for Hepatobiliary Cancers. <i>Hepatology</i> , 2021, 73, 115-127.	3.6	104
58	IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. <i>Gastroenterology</i> , 2016, 151, 1192-1205.	0.6	103
59	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4326-4330.	0.4	99
60	Ras Promotes Growth by Alternative Splicing-Mediated Inactivation of the KLF6 Tumor Suppressor in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 134, 1521-1531.	0.6	96
61	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2021, 160, 2572-2584.	0.6	91
62	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. <i>Gut</i> , 2023, 72, 129-140.	6.1	90
63	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 3740-3752.	2.6	89
64	Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 1824-1826.	3.2	86
65	Liquid biopsy in the clinical management of hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 2025-2034.	6.1	77
66	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 140-151.	2.6	77
67	DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. <i>Clinical Cancer Research</i> , 2015, 21, 925-933.	3.2	74
68	VEGF Signaling in Cancer Treatment. <i>Current Pharmaceutical Design</i> , 2014, 20, 2834-2842.	0.9	74
69	Intratumor Molecular and Phenotypic Diversity in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 1786-1788.	3.2	73
70	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. <i>Gut</i> , 2015, 64, 1296-1302.	6.1	70
71	Mitohormesis Primes Tumor Invasion and Metastasis. <i>Cell Reports</i> , 2019, 27, 2292-2303.e6.	2.9	69
72	Gene Signatures in the Management of Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 473-485.	0.8	68

#	ARTICLE	IF	CITATIONS
73	Effect of HCV clearance with direct-acting antiviral agents on HCC. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 561-562.	8.2	67
74	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 11570.	1.6	64
75	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. <i>British Journal of Cancer</i> , 2019, 121, 340-343.	2.9	62
76	Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. <i>Current Opinion in Oncology</i> , 2008, 20, 444-453.	1.1	60
77	Signaling pathways in hepatocellular carcinoma. <i>Advances in Cancer Research</i> , 2021, 149, 63-101.	1.9	56
78	Depicting the role of TP53 in hepatocellular carcinoma progression. <i>Journal of Hepatology</i> , 2011, 55, 724-725.	1.8	54
79	Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. <i>Hepatology</i> , 2013, 57, 120-130.	3.6	52
80	Molecular Pathogenesis of Hepatocellular Carcinoma. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 821-825.	1.4	47
81	The future of patient-derived tumor xenografts in cancer treatment. <i>Pharmacogenomics</i> , 2015, 16, 1671-1683.	0.6	43
82	The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. <i>JHEP Reports</i> , 2019, 1, 120-130.	2.6	43
83	DNA Methylation Profiling of Human Hepatocarcinogenesis. <i>Hepatology</i> , 2021, 74, 183-199.	3.6	42
84	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. <i>Gut</i> , 2023, 72, 736-748.	6.1	42
85	Liquid biopsy in liver cancer. <i>Discovery Medicine</i> , 2015, 19, 263-73.	0.5	40
86	Signaling Pathways in Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 18-23.	0.9	39
87	Carcinogen-induced hepatic tumors in KLF6+/Δ mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. <i>Hepatology</i> , 2011, 54, 522-531.	3.6	39
88	Why men are at higher risk for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2012, 57, 453-454.	1.8	38
89	Molecular profiling to predict hepatocellular carcinoma outcome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 101-103.	1.4	37
90	Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials. <i>Journal of Hepatology</i> , 2008, 49, 1-5.	1.8	35

#	ARTICLE	IF	CITATIONS
91	Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. <i>World Journal of Gastroenterology</i> , 2013, 19, 1193.	1.4	34
92	Aramchol downregulates stearyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. <i>JHEP Reports</i> , 2021, 3, 100237.	2.6	32
93	Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. <i>Hepatology</i> , 2012, 56, 1361-1370.	3.6	31
94	Inherited hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 725-734.	1.0	28
95	Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. <i>Hepatology</i> , 2019, 70, 2107-2122.	3.6	26
96	The transition from inflammation to cancer in the liver. <i>Clinical Liver Disease</i> , 2016, 8, 89-93.	1.0	25
97	Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing. <i>BMC Medicine</i> , 2020, 18, 200.	2.3	25
98	Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2020, 26, 823-831.	1.3	25
99	The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. <i>Cancers</i> , 2021, 13, 659.	1.7	25
100	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. <i>Gut</i> , 2022, 71, 2069-2080.	6.1	24
101	Safety of Percutaneous Ethanol Injection as Neoadjuvant Therapy for Hepatocellular Carcinoma in Waiting List Liver Transplant Candidates. <i>Transplantation Proceedings</i> , 2005, 37, 3871-3873.	0.3	21
102	Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2019, 14, 62-65.	1.0	21
103	Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 79-83.	0.8	20
104	Rethinking future development of molecular therapies in hepatocellular carcinoma: A bottom-up approach. <i>Journal of Hepatology</i> , 2013, 59, 392-395.	1.8	20
105	Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease→hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. <i>Clinical Liver Disease</i> , 2016, 8, 100-104.	1.0	20
106	Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. <i>Breast Cancer Research</i> , 2019, 21, 56.	2.2	19
107	Lymphotoxins: New Targets for Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 272-273.	7.7	17
108	Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal. <i>Liver Transplantation</i> , 2006, 12, 1747-1754.	1.3	16

#	ARTICLE	IF	CITATIONS
109	Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 2416-2419.	3.6	16
110	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1506-1519.	1.9	16
111	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. <i>PLoS Genetics</i> , 2021, 17, e1009589.	1.5	15
112	miRNA Delivery: Emerging Therapy for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2010, 138, 1202-1204.	0.6	13
113	Divergent evolutionary trajectories in transplanted tumor models. <i>Nature Genetics</i> , 2017, 49, 1565-1566.	9.4	13
114	Digital-resolution and highly sensitive detection of multiple exosomal small RNAs by DNA toehold probe-based photonic resonator absorption microscopy. <i>Talanta</i> , 2022, 241, 123256.	2.9	12
115	Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma. <i>Oncoscience</i> , 2018, 5, 209-211.	0.9	11
116	Update in the Therapeutic Management of Irritable Bowel Syndrome. <i>Digestive Diseases</i> , 2001, 19, 244-250.	0.8	9
117	microRNAs: New ways to block tumor angiogenesis?. <i>Journal of Hepatology</i> , 2012, 57, 490-491.	1.8	9
118	Liver capsule: Molecular-based signatures in hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 2018-2018.	3.6	9
119	A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. <i>Histopathology</i> , 2019, 74, 718-730.	1.6	9
120	Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100364.	2.6	9
121	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2297-2305.	3.2	8
122	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone-Dependent Release of Circulating Tumor DNA. <i>Hepatology Communications</i> , 2021, 5, 1095-1105.	2.0	7
123	Molecular epidemiology in HCV-related hepatocellular carcinoma: First steps. <i>Journal of Hepatology</i> , 2012, 57, 213-214.	1.8	6
124	Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2022, 42, 188-201.	1.8	6
125	Hepatocellular Carcinoma Enters the Sequencing Era. <i>Gastroenterology</i> , 2011, 141, 1943-1945.	0.6	5
126	Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. <i>Journal of Hepatology</i> , 2015, 63, 753-762.	1.8	5

#	ARTICLE	IF	CITATIONS
127	Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors. Scientific Reports, 2020, 10, 5062.	1.6	5
128	Current management of liver cancer. European Journal of Cancer, Supplement, 2007, 5, 444-446.	2.2	4
129	Circulating tumor cells and cholangiocarcinoma. Hepatology, 2016, 63, 23-25.	3.6	4
130	Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation?. Journal of Hepatology, 2017, 67, 893-895.	1.8	4
131	The usual SASPects of liver cancer. Aging, 2015, 7, 348-349.	1.4	4
132	Cell population genetics and deep sequencing: A novel approach for drivers discovery in hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 1198-1200.	1.8	3
133	Clinical Trial Watch: Reports from the Liver Meeting® [®] , AASLD, San Francisco, November 2015. Journal of Hepatology, 2016, 64, 1428-1445.	1.8	3
134	Diagnostic and Prognostic Performance of Liquid Biopsy in Hepatocellular Carcinoma. Current Clinical Pathology, 2017, , 125-135.	0.0	3
135	Molecular profiling of liver cancer heterogeneity. Discovery Medicine, 2017, 24, 117-125.	0.5	3
136	Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular Oncology, 2022, 16, 665-682.	2.1	3
137	Nontumor Prognostic Factors in Hepatocellular Carcinoma. , 2016, , 139-147.		2
138	The Impact of Translational Research in Hepatology. Clinical Liver Disease, 2019, 13, 29-33.	1.0	2
139	Genomic tracing of the elusive liver cancer ancestor. Journal of Hepatology, 2010, 53, 578-579.	1.8	1
140	Genetically engineered mouse models: future tools to predict clinical trial results in oncology?. Future Oncology, 2013, 9, 767-770.	1.1	1
141	Transplantation for hepatocellular carcinoma-worth waiting for?. Liver Transplantation, 2014, 20, 871-873.	1.3	1
142	Novel non-protein biomarkers for early detection of hepatocellular carcinoma. Engineering, 2021, 7, 1369-1369.	3.2	1
143	Selected summary for the 2015 Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE). Hepatic Oncology, 2016, 3, 5-8.	4.2	0
144	Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-24.	0.1	0